Table 3:
Variable | Univariate Analyses |
Multivariate Analyses |
||
---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | |
Agea | 1.12 (0.59–2.12) | .73 | ||
Male | 1.32 (0.26–6.62) | .74 | ||
Enrollment period | 1.02 (0.99–1.04) | .14 | ||
Precarotid stenosisb | 2.02 (1.42–2.87) | <.001 | 2.08 (1.43–3.05) | <.001 |
Hypertension | 0.99 (0.34–2.90) | .99 | ||
Diabetes mellitus | 1.26 (0.45–3.57) | .66 | ||
Hypercholesterolemia | 1.07 (0.39–2.91) | .89 | ||
Coronary artery disease | 1.44 (0.55–3.82) | .46 | ||
Current smoking | 1.05 (0.34–3.28) | .94 | ||
Symptomatic before CAS | 2.02 (0.75–5.45) | .17 | ||
Cilostazol use | 0.18 (0.04–0.85) | .02 | 0.16 (0.03–0.85) | .03 |
Restenosis after CAS | 4.31 (1.11–16.70) | .03 |
Per 10-year increase.
Per 10% increase.